Chemotherapy and hemostasis disorders
Cancer patients are at risk of developing arterial and venous thrombosis during chemotherapy (CT) and after its cessation. A prothrombotic risk may arise via pathogenetic pathways such as activation of external and internal coagulation pathways, decreased anticoagulant levels, platelet activation, f...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2025-01-01
|
| Series: | Акушерство, гинекология и репродукция |
| Subjects: | |
| Online Access: | https://www.gynecology.su/jour/article/view/2288 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849697323934810112 |
|---|---|
| author | E. V. Slukhanchuk V. O. Bitsadze A. G. Solopova J. Kh. Khizroeva K. N. Grigoreva N. R. Gashimova N. A. Makatsariya D. V. Blinov V. N. Galkin A. Yu. Shatilina E. M. Lyadnova N. A. Shulga L. T. Toguzaeva S. Morkos J.-C. Gris I. Elalamy G. Gerotziafas A. D. Makatsariya |
| author_facet | E. V. Slukhanchuk V. O. Bitsadze A. G. Solopova J. Kh. Khizroeva K. N. Grigoreva N. R. Gashimova N. A. Makatsariya D. V. Blinov V. N. Galkin A. Yu. Shatilina E. M. Lyadnova N. A. Shulga L. T. Toguzaeva S. Morkos J.-C. Gris I. Elalamy G. Gerotziafas A. D. Makatsariya |
| author_sort | E. V. Slukhanchuk |
| collection | DOAJ |
| description | Cancer patients are at risk of developing arterial and venous thrombosis during chemotherapy (CT) and after its cessation. A prothrombotic risk may arise via pathogenetic pathways such as activation of external and internal coagulation pathways, decreased anticoagulant levels, platelet activation, fibrinolysis blockade, etc. Chemotherapeutic agents exert direct cytotoxicity, as well as indirectly suppress cellular processes necessary for tumor cell proliferation. CT-related cytotoxicity act on both tumor and healthy body cells. Available targeted drugs with improved selectivity for tumor cells are also associated with thrombosis risk. Low molecular weight heparins, which effectively reduce the risk of venous thromboembolism, have not yet been officially recommended for routine use during CT. Here, we discuss the prothrombotic effects of various antitumor agents aimed at gaining deeper understanding of the underlying mechanisms that may allow to develop new strategies for prevention and treatment of such formidable complications. |
| format | Article |
| id | doaj-art-e02514cbda88407d85d6cceca6e72ca1 |
| institution | DOAJ |
| issn | 2313-7347 2500-3194 |
| language | Russian |
| publishDate | 2025-01-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Акушерство, гинекология и репродукция |
| spelling | doaj-art-e02514cbda88407d85d6cceca6e72ca12025-08-20T03:19:14ZrusIRBIS LLCАкушерство, гинекология и репродукция2313-73472500-31942025-01-0118683584610.17749/2313-7347/ob.gyn.rep.2024.579937Chemotherapy and hemostasis disordersE. V. Slukhanchuk0V. O. Bitsadze1A. G. Solopova2J. Kh. Khizroeva3K. N. Grigoreva4N. R. Gashimova5N. A. Makatsariya6D. V. Blinov7V. N. Galkin8A. Yu. Shatilina9E. M. Lyadnova10N. A. Shulga11L. T. Toguzaeva12S. Morkos13J.-C. Gris14I. Elalamy15G. Gerotziafas16A. D. Makatsariya17Sechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversitySechenov UniversitySechenov Universityinstitute for Preventive and Social Medicine; Moscow Haass Medical - Social Institute; Federal Scientific and Clinical Center for Medical Rehabilitation and BalneologyYudin City Clinical Hospital, Moscow Healthcare DepartmentSechenov UniversitySechenov UniversityLomonosov Moscow State UniversityAcademician Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Health Ministry of Russian FederationAl Zahra HospitalSechenov University; University of MontpellierSechenov University; Medicine Sorbonne University; Hospital TenonSechenov University; Medicine Sorbonne University; Hospital TenonSechenov UniversityCancer patients are at risk of developing arterial and venous thrombosis during chemotherapy (CT) and after its cessation. A prothrombotic risk may arise via pathogenetic pathways such as activation of external and internal coagulation pathways, decreased anticoagulant levels, platelet activation, fibrinolysis blockade, etc. Chemotherapeutic agents exert direct cytotoxicity, as well as indirectly suppress cellular processes necessary for tumor cell proliferation. CT-related cytotoxicity act on both tumor and healthy body cells. Available targeted drugs with improved selectivity for tumor cells are also associated with thrombosis risk. Low molecular weight heparins, which effectively reduce the risk of venous thromboembolism, have not yet been officially recommended for routine use during CT. Here, we discuss the prothrombotic effects of various antitumor agents aimed at gaining deeper understanding of the underlying mechanisms that may allow to develop new strategies for prevention and treatment of such formidable complications.https://www.gynecology.su/jour/article/view/2288cancervenous thromboembolismthrombosischemotherapyст |
| spellingShingle | E. V. Slukhanchuk V. O. Bitsadze A. G. Solopova J. Kh. Khizroeva K. N. Grigoreva N. R. Gashimova N. A. Makatsariya D. V. Blinov V. N. Galkin A. Yu. Shatilina E. M. Lyadnova N. A. Shulga L. T. Toguzaeva S. Morkos J.-C. Gris I. Elalamy G. Gerotziafas A. D. Makatsariya Chemotherapy and hemostasis disorders Акушерство, гинекология и репродукция cancer venous thromboembolism thrombosis chemotherapy ст |
| title | Chemotherapy and hemostasis disorders |
| title_full | Chemotherapy and hemostasis disorders |
| title_fullStr | Chemotherapy and hemostasis disorders |
| title_full_unstemmed | Chemotherapy and hemostasis disorders |
| title_short | Chemotherapy and hemostasis disorders |
| title_sort | chemotherapy and hemostasis disorders |
| topic | cancer venous thromboembolism thrombosis chemotherapy ст |
| url | https://www.gynecology.su/jour/article/view/2288 |
| work_keys_str_mv | AT evslukhanchuk chemotherapyandhemostasisdisorders AT vobitsadze chemotherapyandhemostasisdisorders AT agsolopova chemotherapyandhemostasisdisorders AT jkhkhizroeva chemotherapyandhemostasisdisorders AT kngrigoreva chemotherapyandhemostasisdisorders AT nrgashimova chemotherapyandhemostasisdisorders AT namakatsariya chemotherapyandhemostasisdisorders AT dvblinov chemotherapyandhemostasisdisorders AT vngalkin chemotherapyandhemostasisdisorders AT ayushatilina chemotherapyandhemostasisdisorders AT emlyadnova chemotherapyandhemostasisdisorders AT nashulga chemotherapyandhemostasisdisorders AT lttoguzaeva chemotherapyandhemostasisdisorders AT smorkos chemotherapyandhemostasisdisorders AT jcgris chemotherapyandhemostasisdisorders AT ielalamy chemotherapyandhemostasisdisorders AT ggerotziafas chemotherapyandhemostasisdisorders AT admakatsariya chemotherapyandhemostasisdisorders |